Drug Trial Radar · NCT06862206
A Multicentre, Single Arm, Non-interventional, Real-world Study to Assess Demographic Characteristics and Patient Reported Outcomes in Patients With Severe Eosinophilic Asthma Treated With Benralizumab in China
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
700
Planned (sponsor's estimate)
Start
Jul 11, 2025
Primary completion
Jan 31, 2028
Study completion Jan 31, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Mar 6, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma. The study will focus on the early treatment response, treatment outcomes and the change in asthma control of benralizumab therapy in a real-world setting in China. This study will also describe the physician-reported reasons for discontinuation and switching of benralizumab therapy.
Conditions
- Severe Eosinophilic Asthma
Interventions
benralizumabDrug
non-interventional
Primary outcomes
What the sponsor says the trial is designed to measure.
- asthma control questionnaireTime frame: Week 4
Locations
36 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Anning, China · Recruiting
Research Site
Beijing, China · Recruiting
Research Site
Binzhou, China · Recruiting
Research Site
Changzhou, China · Recruiting
Research Site
Fenyang, China · Recruiting
Research Site
Guangdong, China · Recruiting
Research Site
Guangzhou, China · Recruiting
Research Site
Hangzhou, China · Recruiting
Research Site
Hefei, China · Recruiting
Research Site
Huzhou, China · Recruiting
Research Site
Jiaxing, China · Recruiting
Research Site
Jinan, China · Recruiting
Research Site
Jinhua, China · Recruiting
Research Site
Jining, China · Recruiting
Research Site
Jiyuan, China · Recruiting
Research Site
Kunshan, China · Recruiting
Research Site
Linyi, China · Recruiting
Research Site
Mianyang, China · Recruiting
Research Site
Nanbu, China · Recruiting
Research Site
Nanchang, China · Recruiting
Research Site
Nanjing, China · Recruiting
Research Site
Ningbo, China · Recruiting
Research Site
Shanghai, China · Recruiting
Research Site
Shanxi, China · Recruiting
Research Site
Shenzhen, China · Recruiting
Research Site
Shijiazhuang, China · Recruiting
Research Site
Suining, China · Recruiting
Research Site
Taiyuan, China · Recruiting
Research Site
Weifang, China · Recruiting
Research Site
Wuhan, China · Recruiting
Research Site
Wuxi, China · Recruiting
Research Site
Xi'an, China · Recruiting
Research Site
Xiamen, China · Recruiting
Research Site
Zhangjiagang, China · Recruiting
Research Site
Zhengzhou, China · Recruiting
Research Site
Zhenjiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.